Regeneron's SNS-101 Study Advances Cancer Treatment with Promising Results

Regeneron Pharmaceuticals announced an update on their ongoing Phase 1/2 study of SNS-101, a novel anti-VISTA IgG1 monoclonal antibody, as a standalone treatment and in combination with cemiplimab for advanced solid tumors. The study aims to assess safety and efficacy, with three parts: monotherapy dose escalation, combination dose escalation, and cohort expansion. The study began on May 31, 2023, and is currently active but not recruiting. Positive outcomes could enhance investor confidence and market position in the oncology sector.